Outcomes of stereotactic radiosurgery for pituitary metastases: an international multi-institutional study
Authors' conclusion
SRS is an important modality in the management of PM, offering excellent local tumor control and survival outcomes with minimal morbidity. These findings support the incorporation of SRS into the multidisciplinary management for treating patients with PM.
Study context
- Population
- Patients with pituitary metastases treated with stereotactic radiosurgery (SRS) across 12 institutions; median tumor volume 1.5 cc
- Participants
- 63 patients12 institutions
- Outcome
- Local tumor control rate
- Follow-up
- 12 months
Methodological detailsinternational, 12 institutions
- International
- 12 institutions
Main finding
As reported in the abstract
SRS
93.1%
Observational data: associations, not effects.
Further findings
Survival
- Median survival
- 25.4 months
- OS at 6 months
- 77.6%
- OS at 12 months
- 65.9%
- OS at 18 months
- 55.1%
Margin dose >10 Gy as independent predictor (multivariate analysis)
- Progression-free survival, HR (p < 0.01)
- 0.20
- Distant metastasis-free survival, HR (p = 0.01)
- 0.30
- OS, HR (p < 0.01)
- 0.15
- Multivariate analysis
Visual function after SRS
- Stable or improved visual function
- 17/18
Safety
Complications
- New visual deficits
- 1/63
- New anterior pituitary hormone deficiency
- 5/63
- New arginine vasopressin (AVP)-deficiency
- 2/63
Original publication
Outcomes of stereotactic radiosurgery for pituitary metastases: an international multi-institutional study. Pituitary. Published 29 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →